無法切除的局部晚期或轉移性的三陰性乳癌；泌尿上皮癌。

Antineoplastic Agent, Anti-Trop-2; Antineoplastic Agent, Antibody Drug Conjugate, Topoisomerase I Inhibitor

Distribution: 3.6 L.
Metabolism: SN-38 (small molecule moiety of sacituzumab govitecan) is metabolized via UGT1A1.
Half-life elimination: 23.4 hours; free SN-38: 17.6 hours.
Excretion: 0.13 L/hour.

Severe hypersensitivity to sacituzumab govitecan or any component of the formulation.

Trodelvy is not recommended during pregnancy.

>10%: edema (17% to 19%), alopecia (38% to 49%), pruritus (10% to 17%), skin rash (12% to 32%), decreased serum albumin (32% to 51%), decreased serum glucose (10% to 19%), decreased serum magnesium (18% to 51%), decreased serum phosphate (17% to 41%), decreased serum potassium (22% to 33%), increased lactate dehydrogenase (16% to 28%), increased serum albumin (32%), increased serum glucose (31% to 59%), weight loss (17%), abdominal pain (20% to 31%), constipation (34% to 37%), decreased appetite (21% to 41%), diarrhea (59% to 72%), nausea (57% to 69%), vomiting (23% to 49%), urinary tract infection (13% to 21%), decreased hemoglobin (71% to 94%), decreased platelet count (21% to 30%), decreased neutrophils (67% to 83%), leukopenia (78% to 91%), lymphocytopenia (65% to 88%), prolonged partial thromboplastin time (33% to 60%), increased serum alanine aminotransferase (21% to 35%), increased serum alkaline phosphatase (23% to 57%), increased serum aspartate aminotransferase (15% to 45%), hypersensitivity reaction (35%), infection (50%), dizziness (10% to 22%), fatigue (57% to 68%), headache (16% to 23%), neuropathy (24%), back pain (16% to 23%), acute kidney injury (24%), decreased creatinine clearance (24%), increased serum creatinine (32%), dyspnea (16% to 21%), respiratory tract infection (26%), fever (14% to 19%).

The recommended dose of TRODELVY is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity.

---

Dose modifications for adverse reactions
Severe Neutropenia, Severe Non-Neutropenic Toxicity:
(1) First Occurrence: 25% dose reduction and administer granulocyte-colony stimulating factor (G-CSF).
(2) Second Occurrence: 50% dose reduction.
(3) Third Occurrence: Discontinue treatment.
Severe Neutropenia (At time of scheduled treatment, Grade 3-4 neutropenia which delays dosing beyond 3 weeks for recovery to ≤Grade 1), Severe Non-Neutropenic Toxicity (In the event of Grade 3-4 non-neutropenic hematologic or non-hematologic toxicity, Grade 3 nausea or Grade 3-4 vomiting, which does not recover to ≤ Grade 1 within 3 weeks):
(1) First Occurrence: Discontinue treatment.

No adjustment to the starting dose is required when administering TRODELVY to patients with mild renal impairment.